95.60
+1.60
+(1.70%)
At close: 7:02:18 PM GMT+1
Research Analysis
Earnings Estimate
| Currency in USD | Current Qtr. (Mar 2025) | Next Qtr. (Jun 2025) | Current Year (2025) | Next Year (2026) |
|---|---|---|---|---|
| No. of Analysts | -- | -- | -- | -- |
| Avg. Estimate | 0 | 0 | 0 | 0 |
| Low Estimate | 0 | 0 | 0 | 0 |
| High Estimate | 0 | 0 | 0 | 0 |
| Year Ago EPS | -- | -- | -- | -- |
Revenue Estimate
| Currency in USD | Current Qtr. (Mar 2025) | Next Qtr. (Jun 2025) | Current Year (2025) | Next Year (2026) |
|---|---|---|---|---|
| No. of Analysts | 12 | 12 | 18 | 18 |
| Avg. Estimate | 4.87B | 4.99B | 20.08B | 20.9B |
| Low Estimate | 4.78B | 4.84B | 19.7B | 20.54B |
| High Estimate | 4.91B | 5.1B | 20.33B | 21.21B |
| Year Ago Sales | 5.07B | 5.06B | 20.1B | 20.08B |
| Sales Growth (year/est) | -3.94% | -1.26% | -0.08% | 4.05% |
EPS Trend
| Currency in USD | Current Qtr. (Mar 2025) | Next Qtr. (Jun 2025) | Current Year (2025) | Next Year (2026) |
|---|---|---|---|---|
| Current Estimate | 0 | 0 | 0 | 0 |
| 7 Days Ago | 0 | 0 | 0 | 0 |
| 30 Days Ago | 0 | 0 | 0 | 0 |
| 60 Days Ago | 0 | 0 | 0 | 0 |
| 90 Days Ago | 0 | 0 | 0 | 0 |
EPS Revisions
| Currency in USD | Current Qtr. (Mar 2025) | Next Qtr. (Jun 2025) | Current Year (2025) | Next Year (2026) |
|---|---|---|---|---|
| Up Last 7 Days | -- | -- | -- | -- |
| Up Last 30 Days | -- | -- | -- | -- |
| Down Last 7 Days | -- | -- | -- | -- |
| Down Last 30 Days | -- | -- | -- | -- |
Growth Estimates
| Current Qtr. | Next Qtr. | Current Year | Next Year | |
|---|---|---|---|---|
| 0P59.L | -- | -- | -- | -- |
| S&P 500 | 7.04% | 5.20% | 8.89% | 14.14% |
Upgrades & Downgrades
| Maintains | UBS: Buy to Buy | 4/17/2025 |
| Maintains | Barclays: Equal-Weight to Equal-Weight | 4/11/2025 |
| Maintains | JP Morgan: Overweight to Overweight | 4/11/2025 |
| Maintains | Wells Fargo: Underweight to Underweight | 4/2/2025 |
| Maintains | Piper Sandler: Overweight to Overweight | 3/31/2025 |
| Maintains | Barclays: Equal-Weight to Equal-Weight | 3/27/2025 |